Herein in Philadelphia chromosome positive (Ph+) BCP-ALL PI3K signaling has been shown to be involved in mutation-independent resistance to ABL-directed tyrosine kinase inhibitors [14] and recent preclinical data also suggest a role in Philadelphia chromosome negative (Ph-) BCP-ALL [14, 15]. Here, ABL1 is linked to acute lymphoblastic leukemia.